Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new inhalation device (Concept1) are equivalent to the corresponding dose of formoterol delivered by the Aerolizer device in terms of efficacy, in patients with persistent asthma.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis
• Treatments: Formoterol Fumarate

Criteria

Inclusion Criteria:

• History of asthma attacks

• Forced expiratory volume in 1 second (measure of how well the lungs are working) is greater than 60% of the predicted value

Exclusion Criteria:

• Asthma is not stable: patients were admitted to hospital or received emergency room treatment

• Patients whose asthma drugs need changing within the month prior to the start of the study